Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis

Published:2023-06 Issue:6 Volume:37 Page:108456
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Woodhams Louise M.,Chalmers Leanne,Sim Tin Fei,Yeap Bu B.,Schlaich Markus P.,Schultz Carl,Hillis Graham S.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference43 articles.

1. Diabetic kidney disease: world wide difference of prevalence and risk factors;Gheith;J Nephropharmacol.,2016

2. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

3. The RAAS in the pathogenesis and treatment of diabetic nephropathy;Ruggenenti;Nat Rev Nephrol,2010

4. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy;Brenner;N Engl J Med,2001

5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group;Lewis;N Engl J Med,1993

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal outcomes of combination therapy with sodium-glucose cotransporter 2 inhibitors plus renin-angiotensin system blockers in patients with type 2 diabetes mellitus: A population-based cohort study;2024-08-28

2. Mechanistic Insights into the Synergistic Effects of SGLT-2 Inhibitors and ACE Inhibitors/ARBs: Implications for Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus and Beyond;Journal of Diabetology;2024-07

3. Diabetische Nephropathie 2023 – Beginn eines neuen Zeitalters;Die Diabetologie;2024-05-18

4. Pharmacotherapy before and after bariatric surgery;Metabolism;2023-11

5. Has the time come to step up to “triple therapy” for the treatment of diabetic kidney disease?;Diabetes Research and Clinical Practice;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3